12 Barth subjects aged 12-65

1. Randomization & baseline
2. month 3
3. month 4
4. month 7

- Treatment period 1
- Washout period
- Treatment period 2

- 12 Barth subjects
- Elamipretide 40 mg SC QD
- Placebo SC QD
- Elamipretide 40 mg SC QD

Open-label extension

Endpoints:
- Safety
- 6 minute walk test
- Fatigue patient reported outcome assessments
- 5 time sit-to-stand
- Other patient reported outcome assessments
- Handheld dynamometry
- Echocardiogram

FAST TRACK STATUS RECEIVED 2017